The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

in postmenopausal women with osteoporosis. The study included 2 treatment periods. During the first period, study participants (N=479) were randomly assigned 1:1 to receive denosumab-bmwo or the ...

Osteoporosis, thin weak bones, is common in post-menopausal women and older men. While not fatal, it is a major risk for fractures and can severely impact your quality of life.

A transformative study has uncovered the pivotal role of the protein Naked cuticle homolog 2 (NKD2) in regulating the differentiation of bone-forming osteoblasts and bone-resorbing osteoclasts.

On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...

Romosozumab vs bisphosphonate use was not linked to increased CVD risks among patients with osteoporosis, challenging past concerns over its cardiovascular safety.

The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat ...

Implementing opportunistic computed tomography (CT) bone density screening could increase the osteoporosis screening rate, yielding a reduction in medical costs.

A new study published in the journal of BMC Gasteroenterology found that patients with the liver cirrhosis had higher risk of ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).